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Targeting anandamide metabolism rescues core and
associated autistic-like symptoms in rats prenatally
exposed to valproic acid
M Servadio1, F Melancia1, A Manduca1, A di Masi1, S Schiavi1, V Cartocci1, V Pallottini1, P Campolongo2, P Ascenzi1 and V Trezza1
Autism spectrum disorders (ASD) are characterized by altered sociability, compromised communication and stereotyped/repetitive
behaviors, for which no specific treatments are currently available. Prenatal exposure to valproic acid (VPA) is a known, although still
underestimated, environmental risk factor for ASD. Altered endocannabinoid activity has been observed in autistic patients,
and endocannabinoids are known to modulate behavioral traits that are typically affected in ASD. On this basis, we tested the
hypothesis that changes in the endocannabinoid tone contribute to the altered phenotype induced by prenatal VPA exposure in
rats, with focus on behavioral features that resemble the core and associated symptoms of ASD. In the course of development,
VPA-exposed rats showed early deficits in social communication and discrimination, compromised sociability and social play
behavior, stereotypies and increased anxiety, thus providing preclinical proof of the long-lasting deleterious effects induced by
prenatal VPA exposure. At the neurochemical level, VPA-exposed rats displayed altered phosphorylation of CB1 cannabinoid
receptors in different brain areas, associated with changes in anandamide metabolism from infancy to adulthood. Interestingly,
enhancing anandamide signaling through inhibition of its degradation rescued the behavioral deficits displayed by VPA-exposed
rats at infancy, adolescence and adulthood. This study therefore shows that abnormalities in anandamide activity may underlie the
deleterious impact of environmental risk factors on ASD-relevant behaviors and that the endocannabinoid system may represent a
therapeutic target for the core and associated symptoms displayed by autistic patients.
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INTRODUCTION
Autism spectrum disorders (ASD) are a group of severe develop-
mental psychiatric disorders emerging in the early life, for which
no specific treatments are currently available. ASD are charac-
terized by altered social interaction, compromised verbal and
nonverbal communication, stereotyped and repetitive behaviors,1
often associated with comorbid features,2–4 such as social and
generalized anxiety.5–7
Both genetic and environmental factors are involved in the
etiology of ASD.8,9 Environmental factors include a broad range of
influences, such as prenatal exposure to drugs, environmental
chemicals, infectious agents, or maternal stress.10 One of the best
examples of known environmental risk factors for ASD is prenatal
exposure to the antiepileptic and mood stabilizer drug valproic
acid (VPA). When this drug is taken during pregnancy, it can result
in children displaying autistic-like features, such as impaired
communication, reduced sociability and stereotyped behaviors.11,12
Results from animal models support the clinical data: prenatal VPA
exposure in rodents induces autistic-like signs in the offspring, and
therefore it has been proposed as a preclinical model of ASD with
face and construct validity.13–16 However, the public awareness of
the association between prenatal VPA exposure and adverse
outcome in the offspring is still limited. Thus, in March 2016, the
French Inspection générale des affaires sociales reported at least
450 cases of malformations in children born between 2006 and
2014 from mothers who had taken VPA during pregnancy,17
calling for additional research on both environmental risk factors
for ASD that can become targets for effective public health risk
reduction efforts, and potential treatments for VPA-induced
neurobehavioral dysfunctions.
The endocannabinoid system is a unique biological system that
affects a wide range of biological processes, including brain
development and functioning. It consists of cannabinoid receptors
(CB1 and CB2, mainly expressed in the brain and periphery,
respectively), their endogenous ligands (endocannabinoids,
mainly anandamide and 2-arachidonoylglycerol (2-AG)), and the
enzymes for ligand synthesis and degradation.18–21 In the present
study, we used the rat model of ASD based on prenatal VPA
exposure to test the hypothesis that an altered endocannabinoid
tone contributes to the behavioral alterations observed in ASD, for
the following reasons: (1) endocannabinoids are key modulators
of socio-emotional responses, cognition, seizure susceptibility,
nociception and neuronal plasticity,22–25 all of which are affected
in ASD; (2) variations in the CB1 cannabinoid receptor gene
modulate social reward responsivity in reward-related forebrain
areas,26,27 suggesting that subtle changes in endocannabinoid
affinity at CB1 receptors owing to these polymorphisms may
underlie the deficits in social reward processing observed in ASD;
(3) altered endocannabinoid activity has been observed both in
genetic28–31 and environmental32 models of ASD and in ASD
patients.33
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We first determined whether the autistic-like behavioral
changes exhibited through development by rats prenatally
exposed to VPA were associated with changes in the activity of
CB1 cannabinoid receptors in brain areas involved in socio-
emotional functioning. The endocannabinoid anandamide has a
positive modulatory role in key behaviors that are altered in ASD,
such as social communication, social play and anxiety-like
behaviors,34–39 and it has recently been shown that pharmacolo-
gical enhancement of anandamide levels corrected the social
deficits observed in two genetic models of ASD.40 Therefore, we
investigated whether prenatal VPA exposure induced changes in
brain anandamide synthesis and metabolism, and whether
pharmacological manipulation of the endocannabinoid system
through modulation of anandamide metabolism was able to
restore the altered phenotype displayed by VPA-exposed rats from
infancy to adulthood, with focus on behavioral features that
resemble the core and associated symptoms of ASD.
MATERIALS AND METHODS
Animals
Female Wistar rats (Charles River, Arbresle, France), weighing 250± 15 g,
were mated overnight. The morning when spermatozoa were found was
designated as gestational day 1. Pregnant rats were singly housed in
Macrolon cages (40 (length) × 26 (width) × 20 (height) cm), under
controlled conditions (temperature 20–21 °C, 55–65% relative humidity
and 12/12 h light cycle with lights on at 0700 h). Food and water were
available ad libitum. On gestational day 12.5, females received a single
intraperitoneal injection of either sodium valproate (VPA) or saline (SAL).
Newborn litters found up to 1700 h were considered to be born on that
day (postnatal day (PND) 0). On PND 1, the litters were culled to eight
animals (six males and two females), to reduce the litter size-induced
variability in the growth and development of pups during the postnatal
period. On PND 21, the pups were weaned and housed in groups of three.
The experiments were carried out on the male offspring during infancy
(PNDs 9 and 13), adolescence (PND 35) and adulthood (PND 90). One pup
per litter from different litters per treatment group was used in each
experiment. For every experiment, the exact sample size (n) for each
experimental group/condition is indicated in the figure legends. The
sample size was based on our previous experiments and power analysis.
The experiments were performed in Wistar rats because previous
behavioral studies performed with the VPA preclinical model of autism
used this rat strain.15 Furthermore, we focused on behavioral features,
resembling the core and associated symptoms of ASD, that are well
documented and can be easily studied in the Wistar rat strain, either from
an ethological or pharmacological point of view.
The experiments were approved by the Italian Ministry of Health (Rome,
Italy) and performed in agreement with the guidelines released by the
Italian Ministry of Health (D.L. 26/14) and the European Community
Directive 2010/63/EU.
Drugs
VPA (Cayman Chemical, Ann Arbor, MI, USA) was dissolved in saline at a
concentration of 250 mg ml− 1 and administered at a dose (500 mg kg− 1)
and time (gestational day 12.5) that have been shown to induce autistic-
like behavioral changes in the offspring.41
The anandamide hydrolysis inhibitor URB597 (Sigma-Aldrich, Milan, Italy)
was dissolved in 5% Tween 80/5% polyethylene glycol/saline and
administered intraperitoneally either 2 h (for the behavioral tests
performed at adolescence and adulthood) or 30 min (for the behavioral
tests performed at infancy) before testing. Drug dose and pre-treatment
intervals were based on literature,29,35,37,38,42 and on pilot experiments. The
solutions were administered in a volume of 2.5 ml kg− 1 at infancy,
2 ml kg− 1 at adolescence and 1 ml kg− 1 at adulthood.
Western blot analysis of phosphorylated and total CB1
cannabinoid receptor
The rats were rapidly decapitated and their brains removed and cut into
coronal slices on a cold plate. The prefrontal cortex, dorsal striatum,
nucleus accumbens, hippocampus, amygdala and cerebellum were
dissected by hand under microscopic control within 2 min. The tissues
were stored at − 80 °C until use.
Lysates from the tissues were homogenized in a homogenization buffer
(0.01 M Tris-HCl, 0.001 M CaCl2, 0.15 M NaCl, 0.001 M PMSF (phenylmethyl-
sulfonyl fluoride), pH 7.5) w/v 1:10 (ref. 43) by sonication. An aliquot
of homogenate was resuspended in sample buffer (0.250 M Tris-HCl—pH
6.8—containing 20% SDS, 0.001 M PMSF). Lysate samples were
boiled for 5 min before loading to the SDS-PAGE (polyacrylamide gel
electrophoresis).
Proteins (20 μg) from lysate samples were resolved by 7% SDS-PAGE at
30 mA (constant current) for 120 min and blotted to nitrocellulose
membranes (Bio-Rad, Hercules, CA, USA). Immunoblots were incubated
with primary antibodies anti P-CB1 and CB1 (1:500; Santa Cruz
Biotechnology, Santa Cruz, CA, USA, Catalog No. sc-17555 and sc-10068),
followed by secondary peroxidase-conjugated antibodies (1:3000; Santa
Cruz Biotechnology, Catalog No. sc-2020). Immunoreactivity was detected
by enhanced chemiluminescence (GE Healthcare, Little Chalfont, UK). The
nitrocellulose membrane was stripped with Restore western blot stripping
buffer (Pierce Chemical, Rockford, IL, USA) for 15 min at room temperature
and re-probed with anti-tubulin (Sigma, Catalog No. T9026) antibody.
Bound antibodies to proteins onto nitrocellulose were visualized by using
enhanced chemoluminescence detection (GE Healthcare) and exposure to
Amersham Hyperfilm ECL (GE Healthcare). The images were analyzed with
ImageJ (National Institutes of Health).
Quantitative PCR analysis of fatty acid amide hydrolase and
N-acylphosphatidylethanolamines-phospholipid D expression
Two micrograms of the total RNA extracted from the whole rat brain were
reverse-transcribed using an oligo-dT primer to prime the reverse
transcription and the SuperScript II Reverse Transcriptase system (Life
Technologies). The quantitative PCR (qPCR) of fatty acid amide hydrolase
(FAAH) and N-acylphosphatidylethanolamines-phospholipid D (NAPE-PLD)
was performed using a Rotor-Gene 6000 thermal cycling system (Corbett
Research, Mortlake, NSW, Australia) and the Hydra SYBR qPCR Master Mix
(BioLab, Rome, Italy) as detection system. The thermal cycling conditions
for all the transcripts analyzed were: 95 °C for 2 min and 40 cycles at 95 °C
for 10 s and 60 °C for 30 s. PCR primers were the following: FAAH_FW:
5’-TGCTGAAGCCTCTGTTTCCT-3’; FAAH_RV: 5’-TCTCATGCTGCAGTTTCCAC;
NAPE_FW: 5’-TCGCTGGGGATACTGGTTAC-3’; NAPE_RV: 5’-AAGCTCCAATGG
GAATAGCC; β-ACTIN_FW: 5’-AGGCCATGTACGTAGCCATCCA-3’; β-ACTIN_RV:
5’-TCTCCGGAGTCCATCACAATG-3’. The fold changes of FAAH and NAPE
transcripts expression in VPA- vs SAL-treated samples were calculated
using the 2–ΔΔCT method.
Reproduction data
Body weights of the dams were taken daily throughout pregnancy and the
length of pregnancy was determined. Litter size, male/female ratio, weight
gain of pups and postnatal vitality were also measured.
Isolation-induced ultrasonic vocalizations
On PND 9, the pups were individually placed into a Plexiglas arena (30
(length) × 30 (width) × 30 (height) cm), located inside a sound-attenuating
and temperature-controlled chamber, with a camera positioned above the
arena. The ultrasonic vocalizations (USVs) emitted by the pup were
detected for 3 min by an ultrasound microphone (Avisoft Bioacoustics,
Glienicke, Germany) sensitive to frequencies between 10 and 200 kHz. Pup
axillary temperature was measured before and after the test by a digital
thermometer. The USVs were analyzed, both quantitatively and qualita-
tively, using Avisoft Recorder software (Version 5.1), and classified in six
different groups according to number of syllables, frequency modulation
and duration:44–46 flat calls (calls with constant frequency with a maximum
variation of ± 5 kHz ); up/downward (single syllable calls emitted at ± 5 kHz
with a single frequency modulation); flat high frequency calls (calls with
similar constant frequency, but emitted at 475 kHz); syllable calls (calls
composed by two or more syllables); complex calls (calls displaying
complex frequency modulation); short calls (calls with durations shorter
than 5 ms).
Homing behavior
On PND 13, the litter was separated from the dam and kept for 30 min in a
temperature-controlled holding cage. Then, each pup was placed into a
Plexiglas box whose floor was one-third covered with bedding from the
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pup’s home cage and two-third with clean bedding. The pup was
located at the side of the box covered by clean bedding, and its behavior
was videorecorded for 4 min for subsequent analysis. The following
parameters were scored using the Observer 3.0 software (Noldus
Information Technology, Wageningen, The Netherlands): latency (seconds)
to reach the home-cage bedding area; total time (seconds) spent by the
pup in the nest bedding area; total number of entries into the nest
bedding area.45
Three-chamber test
The apparatus was a rectangular three-chamber box, with two lateral
chambers (30 (length) × 35 (width) × 35 (height) cm) connected to a central
chamber (15 (length) × 35 (width) × 35 (height) cm). Each lateral chamber
contained a small Plexiglas cylindrical cage. The test was performed as
previously described.47 Each experimental rat was individually allowed to
explore the apparatus for 10 min, and then confined in the central
compartment. An unfamiliar stimulus animal was placed into the Plexiglas
cage in one chamber of the apparatus, whereas the cage in the other
chamber was left empty. Both doors to the side chambers were then
opened, allowing the experimental animal to freely explore the apparatus
for 10 min. The percent of time spent in social approach (sniffing the
stimulus and the cage confining it) was scored using the Observer 3.0
software (Noldus Information Technology).
Social play behavior
Rats were individually habituated to the test cage for 10 min on each of
the 2 days before testing, as previously described.37,42,48 On the test day,
the animals were isolated for 3 h before testing.49–51 The test consisted of
placing VPA- or SAL-exposed rats together with an untreated animal for
15 min. The behavior was assessed for each individual animal of a pair
separately using the Observer 3.0 software (Noldus Information Technol-
ogy). The behaviors of the animals were recorded using a camera with
zoom lens, video tape recorder and television monitor.
In rats, a bout of social play behavior starts with one rat soliciting
(‘pouncing’) another animal, by attempting to nose or rub the nape of its
neck. The animal that is pounced upon can respond in different ways: if the
animal fully rotates to its dorsal surface, ‘pinning’ is the result (one animal
lying with its dorsal surface on the floor with the other animal standing
over it), which is considered the most characteristic posture on social play
behavior in rats.52
We determined ‘play responsiveness’ (that is, the percentage of
response to play solicitation) as the probability of an animal of being
pinned in response to play solicitation (pouncing) by the stimulus
partner.42
Elevated plus maze
The apparatus comprised two open and two closed arms (50 (length) × 10
(width) × 40 (height) cm) that extended from a common central platform
(10 (length) × 10 (width) cm). The rats were individually placed on the
central platform of the maze for 5 min. Each session was recorded with a
camera positioned above the apparatus for subsequent behavioral analysis
performed using the Observer 3.0 software (Noldus Information Technol-
ogy). The following parameters were analyzed:53
1. % time spent in the open arms (% TO): (seconds spent on the open
arms of the maze/seconds spent on the open+closed arms) × 100;
2. % open-arm entries (% OE): (the number of entries into the open arms
of the maze/number of entries into open+closed arms) × 100;
3. Number of closed-arm entries (number of CE).
Hole-board test
The apparatus was a gray square metal table (40 (length) × 40 (width) × 10
(height) cm) with 16 evenly spaced holes (4 cm in diameter), inserted in a
Plexiglas arena (40 (length) × 40 (width) × 60 (height) cm). The rats were
individually placed in the apparatus and their behavior was observed for
5 min. Dipping behavior was scored by the number of times an animal
inserted its head into a hole at least up to the eye level. Each session was
recorded with a camera positioned above the apparatus for subsequent
behavioral analysis performed using the Observer 3.0 software (Noldus
Information Technology).
Statistical analysis
The data are expressed as mean± s.e.m. To assess the effects of the
prenatal treatment (VPA or SAL) on the offspring, data were analyzed with
Student’s t-tests. Two-way analysis of variance (ANOVA) was used to assess
the effects of prenatal and postnatal treatments, using prenatal (VPA or
SAL) and postnatal (URB597 or vehicle) treatments as between-subjects
factor. Two-way ANOVA was followed by Student's–Newman–Keuls post
hoc test where appropriate.
The western blot and qPCR experiments were performed in duplicate
and the results were comparable.
Behavioral experiments were scored and analyzed by a trained observer
who was unaware of the treatment conditions (Noldus Information
Technology). Similarly, biochemical experiments were performed and
analyzed in blinded conditions.
Supplementary Figure 1 shows three different timeline diagrams for:
(1) the behavioral characterization of the VPA- and SAL-exposed offspring;
(2) the behavioral effects of URB597 in the VPA- and SAL-exposed
offspring; (3) the western blot and quantitative PCR analyses of the brain of
VPA- and SAL-exposed animals.
RESULTS
Reproduction data
During gestation, no differences in body weight gains were
observed between VPA- and SAL-treated dams. Prenatal VPA
exposure did not affect pregnancy length, litter size at birth,
male/female ratio, pup weight gain and postnatal vitality
(Supplementary Table 1).
CB1 cannabinoid receptor phosphorylation and FAAH and
NAPE-PLD expression
Phosphorylation may reflect the activation of CB1 cannabinoid
receptors.54 To investigate whether VPA prenatal exposure
induced changes in the activity of brain cannabinoid receptors,
we measured both phosphorylated and total CB1 receptor protein
expression in the prefrontal cortex, dorsal striatum, nucleus
accumbens, hippocampus, amygdala and cerebellum of the
offspring at PNDs 13, 35 and 90. In VPA-exposed rats, the ratio
between phosphorylated and total CB1 receptor protein
decreased in the amygdala at PND 13 (t= 2.103, Po0.05,
df = 10; Figure 1a) and 90 (t= 11.41, Po0.001, df = 10; Figure 1c)
but not at PND 35 (t= 0.06718, P=NS (not significant), df = 10) and
in the hippocampus at PND 35 (t= 3.439, Po0.01, df = 10;
Figure 1e) and PND 90 (t= 4.802, Po0.001, df = 10; Figure 1f),
but not at PND 13 (t= 1.369, P=NS, df = 10). The phosphorylation
state of CB1 receptors increased in the dorsal striatum of VPA-
exposed rats at all ages (PND 13: t= 6.056, Po0.001, df = 10;
Figure 1g; PND 35: t= 4.082, Po0.001, df = 10; Figure 1h; PND 90:
t= 5.601, Po0.001, df = 10; Figure 1i). No differences between
VPA- and SAL-exposed rats were observed in the cerebellum (PND
13: t= 0.8856, P=NS, df = 10; PND 35: t= 0.05827, P=NS, df = 10;
PND 90: t= 0.8579, P=NS, df = 10), prefrontal cortex (PND 13:
t= 1.897, P=NS, df = 10; PND 35: t= 0.1135, P=NS, df = 10; PND 90:
t= 0.8790, P=NS, df = 10) and nucleus accumbens (PND 13:
t= 0.3687, P=NS, df = 10; PND 35: t= 0.1578, P=NS, df = 10; PND
90: t= 1.365, P=NS, df = 10). Significant changes in CB1 total
receptor levels were only observed in the striatum of adolescent
(t= 5.88, P=NS, df = 10) and adult (t= 2.47, P=NS, df = 10) rats and
in the hippocampus of adult animals (t= 4.15, P=NS, df = 10).
We next evaluated the expression of FAAH, which catalyzes
anandamide hydrolysis, and NAPE-PLD, which catalyzes the one-
step conversion of NAPEs to anandamide, in the brain of the
offspring at PNDs 13, 35 and 90. In VPA-exposed animals, FAAH
expression was increased at PND 13 (t= 3.8832, Po0.05, df = 4)
and unchanged at PNDs 35 (t= 0.6928, P=NS, df = 4) and 90
(t= 2.6943, P=NS, df = 4; Figure 2a). NAPE-PLD expression was
decreased in VPA-exposed animals at all ages (PND 13: t= 11.2583,
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Po0.001, df = 4; PND 35: t= 18.0133, Po0.001, df = 4; PND 90:
t= 11.1207, Po0.001, df = 4; Figure 2b).
Isolation-induced USVs
When separated from the dam and siblings on PND 9, VPA-
exposed pups vocalized significantly less compared with SAL-
exposed pups (t= 2.15, Po0.05, df = 28; Figure 3a). No differences
between the two groups were found in the percentage of the
different call categories emitted: flat (t= 0.82, P=NS, df = 14); flat
high frequency (t= 1.54, P=NS, df = 14); syllable (t= 0.69, P =NS,
df = 14); short (t= 1.08, P=NS, df = 14); up/downward (t= 0.67,
P=NS, df = 14); complex (t= 0.04, P=NS, df = 14). URB597 reversed
the communicative deficits displayed by VPA-exposed animals,
without altering the performance of SAL-exposed pups
(Figure 3b). A two-way ANOVA analysis performed on the number
of total USVs emitted after treatment with URB597 or vehicle gave
the following results: total USVs (F(prenatal treat.)1,38 = 2.021, P=NS;
F(treat.)1,38 = 2.741, P=NS; F(prenatal treat. × treat.)1,38 = 4.586; Po0.05).
Post hoc analysis revealed that VPA-exposed pups emitted less
USVs compared with SAL-exposed pups (Po0.05). However,
VPA-exposed pups treated with URB597 did not differ from SAL-
exposed pups treated with either VEH (P=NS) or URB (P=NS;
Figure 3b).
Homing behavior
The VPA-exposed rats showed deficits in the homing test on PND
13: they showed longer latency to reach the home-cage bedding
(t= 2.55, Po0.05, df = 23; Figure 3c) and spent less time in the
nest area (t= 2.55, Po0.05, df = 23; not shown) compared with
SAL-exposed offspring. The two groups did not differ in locomotor
activity (number of crossings: t= 0.90, P=NS, df = 23). URB597
reversed the deficit displayed by VPA-exposed pups in this test,
without altering the performance of SAL-exposed pups. A two-
way ANOVA analysis performed on the parameters measured in
the test gave the following results: latency (F(prenatal treat.)1,40 = 1.77,
P=NS; F(treat.)1,40 = 5.45, Po0.05; F(prenatal treat. × treat.)1,40 = 3.53;
Figure 1. Activation of CB1 receptors. Ratio between phosphorylated and total CB1 receptor protein in the amygdala (a–c), hippocampus (d–f)
and dorsal striatum (g–i) of VPA- and SAL-exposed offspring, evaluated at PNDs 13 (n (SAL)= 6, n (VPA)= 6), 35 (n (SAL)= 6, n (VPA)= 6) and 90
(n (SAL)= 6, n (VPA)= 6). Data represent mean± s.e.m.; *Po0.05; **Po0.01; ***Po0.001 (Student’s t-test). PND, postnatal day; SAL, saline;
VPA, valproic acid.
Anandamide and autism spectrum disorders
M Servadio et al
4
Translational Psychiatry (2016), 1 – 11
P=NS); nesting time (F(prenatal treat.)1,40 = 1.34, P=NS; F(treat.)1,40 =
6.72, Po0.05; F(prenatal treat. × treat.)1,40 = 7.11; Po0.05). Post hoc
analysis revealed that VPA-exposed pups showed a longer latency
to reach the familiar bedding (Po0.05; Figure 3d) and spent less
time in the nest area (Po0.01, not shown) compared with
SAL-exposed pups. Conversely, no differences were found
between VPA-exposed pups treated with URB597 and SAL-
exposed pups treated with vehicle.
Social play behavior
The VPA-exposed rats showed reduced play responsiveness
compared with SAL-exposed animals (t= 2.56, Po0.05, df = 24;
Figure 3e). When VPA- and SAL-exposed animals were treated
with URB597 or its vehicle, a two-way ANOVA analysis performed
on the percentage of response to play solicitation gave the
following results: (F(prenatal treat.)1,32 = 4.42, Po0.05; F(treat.)
1,32 = 4.52, Po0.05; F(prenatal treat. × treat.)1,32 = 1.2; P=NS). Post hoc
analysis revealed that VPA-exposed rats responded less to social
play solicitation (Po0.05; Figure 3f) compared with SAL-exposed
rats. Conversely, no differences were found between VPA-exposed
rats treated with URB597 and SAL-exposed rats treated with
vehicle.
Three-chamber test
Compared with the SAL-exposed animals, the VPA-exposed rats
showed decreased sociability in the three-chamber test, as they
spent less time sniffing the stimulus animal both at PNDs 35
(t= 3.14, Po0.01, df = 15; Figure 4a) and 90 (t= 3.37, Po0.01,
df = 26; Figure 4c). No differences between the two groups were
found in the total number of entries (PND 35: t= 0.13, P=NS,
df = 15; PND 90: t= 1.44, P=NS, df = 26, not shown). When VPA-
and SAL-exposed animals were treated with URB597 or its vehicle,
a two-way ANOVA analysis performed on the percentage of time
spent sniffing the stimulus gave the following results: PND 35
(F(prenatal treat.)1,40 = 6.05, Po0.05; F(treat.)1,40 = 9.31, Po0.01;
F(prenatal treat. × treat.)1,40 = 2.1; P=NS); PND 90 (F(prenatal treat.)1,35 =
4.13, Po0.05; F(treat.)1,35 = 1.07, P=NS; F(prenatal treat. × treat.)1,35 = 1.1;
P=NS). Post hoc analysis revealed that VPA-exposed rats spent
less time sniffing the stimulus than SAL-exposed rats both at PND
35 (Po0.01; Figure 4b) and PND 90 (Po0.05; Figure 4d).
Conversely, no differences were found between VPA-exposed rats
treated with URB597 and animals SAL-exposed rats treated with
vehicle.
Hole-board test
The VPA-exposed rats showed stereotypic behaviors in the hole-
board test, as they made more head dippings at PND 35 (t= 4.14,
Po0.001, d.f. = 21; Figure 4e) and PND 90 (t= 2.27, Po0.05,
df = 22; Figure 4g). URB597 reduced the stereotypic behavior
found in VPA-exposed rats. A two-way ANOVA analysis performed
on the number of head dippings gave the following results:
PND 35 (F(prenatal treat.)1,74 = 3.93, P=NS; F(treat.)1,74 = 4.6, Po0.05;
F(prenatal treat. × treat.)1,74 = 10.49; Po0.01); PND 90 (F(prenatal treat.)1,30 =
1.32, P=NS; F(treat.)1,30 = 10.67, Po0.01; F(prenatal treat. × treat.)1,30 = 4.82;
Po0.05). Post hoc analysis revealed that VPA-exposed adolescent
(Po0.001; Figure 4f) and adult (Po0.05; Figure 4h) rats made
more head dippings than SAL-exposed rats. Conversely, no
differences were found between VPA-exposed rats treated with
URB597 and SAL-exposed rats treated with vehicle.
Elevated plus maze test
Both at PNDs 35 and 90, the VPA-exposed rats showed an anxious-
like phenotype compared with SAL-exposed animals, as they
spent less time in the open arms (PND 35: t= 3.18, Po0.01,
df = 42; Figure 5a; PND 90: t= 2.55, Po0.05, df = 21; Figure 5e) and
made less open-arm entries (PND 35: t= 2.08, Po0.05, df = 42;
Figure 5b; PND 90: t= 2.86, Po0.01, df = 21; Figure 5f) compared
to SAL-exposed rats. No significant differences have been found in
the total number of closed-arm entries either at PND 35 (t= 1.64,
P=NS, df = 42, data not shown) or 90 (t= 0.65, P=NS, df = 21, data
not shown). URB597 had anxiolytic-like effects in VPA-exposed
rats, without altering the behavior of SAL-exposed animals. A
two-way ANOVA analysis performed on the parameters measured
in this test gave the following results: PND 35, percentage of
time spent in the open arms (F(prenatal treat.)1,34 = 6.09, Po0.05;
F(treat.)1,34 = 1.41, P=NS; F(prenatal treat. × treat.)1,34 = 2.87, P=NS);
percentage of open-arm entries (F(prenatal treat.)1,34 = 8.60, Po0.01;
F (treat.)1,34 = 5.93, Po0.05; F(prenatal treat. × treat.)1,34 = 4.51, Po0.05);
PND 90, percentage of time spent in the open arms
(F(prenatal treat.)1,54 = 2.12, P=NS; F(treat.)1,54 = 5.79, Po0.05;
F(prenatal treat. × treat.)1,54 = 8.08, Po0.05; Figure 5g); percentage of
open-arm entries (F(prenatal treat.)1,54 = 1.76, P=NS; F(treat.)1,54 = 1.85,
P=NS; F(prenatal treat. × treat.)1,54 = 5.84, Po0.05; Figure 5h). Post hoc
analysis showed that VPA-exposed animals spent less time in the
open arms and made less open-arm entries compared with
SAL-exposed rats (Figures 5c and d, g and h). Conversely, no
differences were found between VPA-exposed animals
treated with URB597 and SAL-exposed animals treated either
with vehicle or with URB. Last, a two-way ANOVA analysis
performed on the total number of closed-arm entries gave the
following results: adolescence (F(prenatal treat.)1,34 = 1.2, P=NS;
F(treat.)1,34 = 0.45, P=NS; F(prenatal treat. × treat.)1,34 = 0.06, P=NS);
adulthood (F(prenatal treat.)1,54 = 1.1, P=NS; F(treat.)1,54 = 0.36, P=NS;
F(prenatal treat. × treat.)1,54 = 0.17, P=NS).
Figure 2. FAAH and NAPE-PLD expression. Fold induction of FAAH
(a) and NAPE-PLD (b) expression in the brain of VPA- and SAL-
exposed offspring, evaluated at PNDs 13 (n (SAL)= 3, n (VPA)= 3), 35
(n (SAL)= 3, n (VPA)= 3) and 90 (n (SAL)= 3, n (VPA)= 3). Data
represent mean± s.d.; *Po0.05; ***Po0.001 (Student’s t-test).
FAAH, fatty acid amide hydrolase; NAPE-PLD, N-acylphosphatidy-
lethanolamines-phospholipid D; PND, postnatal day; SAL, saline;
VPA, valproic acid.
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Figure 3. Isolation-induced USV, homing and social play behavior tests. Prenatal VPA exposure reduced isolation-induced USV emission at PND
9 (a; n (SAL)= 13, n (VPA)= 17), altered homing behavior at PND 13 (c; n (SAL)= 10, n (VPA)= 15) and reduced social play behavior at PND 35 (e;
n (SAL)= 14, n (VPA)= 12). URB597 reversed the altered behavioral phenotype displayed by VPA-exposed rats in the isolation-induced USV (b;
n (SAL-VEH)= 12, n (VPA-VEH)= 11, n (SAL-URB)= 10, n (VPA-URB)= 9), homing (d; n (SAL-VEH)= 11, n (VPA-VEH)= 11, n (SAL-URB)= 14, n (VPA-
URB)= 8) and social play behavior (f; n (SAL-VEH)= 9, n (VPA-VEH)= 11, n (SAL-URB)= 8, n (VPA-URB)= 8) tests. Data represent mean± s.e.m.
*Po0.05 vs SAL-VEH group; §Po0.05, §§Po0.01 vs VPA-VEH group (Student’s t-test (a, c, e); Student's–Newman–Keuls post hoc test (b, d, f)).
PND, postnatal day; SAL, saline; USV, ultrasonic visualization; VEH, vehicle; VPA, valproic acid.
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DISCUSSION
Endocannabinoids are known to regulate key brain functions that
are altered in ASD. By using a well-validated animal model of ASD
based on prenatal VPA exposure in rats,15,16 we provide new
evidence that an altered anandamide tone that manifests already
at infancy and persists into adolescence and adulthood may
underlie core and associated autistic-like symptoms, thus provid-
ing preclinical rationale to a potential role of anandamide
signaling as a new therapeutic target for ASD.
At the neurochemical level, we found that rats prenatally
exposed to VPA display altered expression of phosphorylated CB1
cannabinoid receptors in the amygdala, hippocampus and dorsal
striatum, with no changes in the prefrontal cortex, cerebellum and
nucleus accumbens. As phosphorylation may reflect the activation
of CB1 cannabinoid receptors,54 the observed changes may be a
compensatory response aimed at normalizing CB1-mediated
signaling in VPA-exposed rats as a consequence of a relative
imbalance of the system.55 To support this possibility, we found
changes in the expression of the enzymes that catalyze the
synthesis and degradation of anandamide in the brain of infant,
adolescent and adult rats prenatally exposed to VPA, indicating
that prenatal VPA exposure induces long-lasting changes in brain
anandamide metabolism. These results extend previous findings
showing changes in the expression of mRNA for the enzymes
primarily responsible for the synthesis and degradation of 2-AG in
the cerebellum and hippocampus of VPA-exposed rats, with no
changes in both 2-AG and anandamide content.32
At the behavioral level, our results confirm the validity of
prenatal exposure to VPA as an animal model of ASD with strong
face validity. In particular, our longitudinal study shows that
prenatal VPA exposure induces early communicative deficits,
altered sociability and social play behavior, enduring stereotypies
and increased anxiety in the rat offspring. At infancy, in line with
previous studies,56–59 we found quantitative changes in the USVs
emitted by VPA-exposed rats when separated from their mother
and siblings compared with control animals. USVs have an
essential communicative role in mother–offspring interaction,60
and therefore the altered USV profile displayed by VPA-exposed
pups when separated from the nest may indicate a reduced ability
to communicate with their mother. Furthermore, as previously
reported,15,58,61–63 we found that VPA-exposed pups were unable
to use olfactory cues to discriminate between a neutral odor and
their own home cage odor in the homing behavior test. Olfaction,
and in particular the learned association between maternal odors
and maternal stimulation, is crucial for the development of social
behavior and social recognition.64,65 Altogether, the altered USV
profile and homing behavior displayed by VPA-exposed pups
indicate their profound deficits in social communication and social
discrimination since the first days of life.
At adolescence and adulthood, the consequences of prenatal
VPA exposure on the social behavior of the offspring were
analyzed at two different levels: (1) during a free dyadic social
encounter with a same-age stimulus animal, to analyze the
reciprocal nature of the social interaction and its ethologic
Figure 4. Three-chamber and hole-board tests. Prenatal VPA exposure reduced sociability in the three-chamber test (a and c) at PND 35 (n
(SAL)= 8, n (VPA)= 9) and 90 (n (SAL)= 15, n (VPA)= 13) and induced stereotypic behavior in the hole-board test (e and g) at PND 35 (n
(SAL)= 11, n (VPA)= 12) and 90 (n (SAL)= 12, n (VPA)= 12). URB597 mitigated the altered sociability (b and d) displayed by VPA-exposed
offspring at PND 35 (n (SAL-VEH)= 13, n (VPA-VEH)= 13, n (SAL-URB)= 8, n (VPA-URB)= 10) and 90 (n (SAL-VEH)= 11, n (VPA-VEH)= 12, n (SAL-
URB)= 8, n (VPA-URB)= 8). Furthermore, URB597 mitigated the stereotypies (f and h) displayed by VPA-exposed offspring at PND 35 (n (SAL-
VEH)= 20, n (VPA-VEH)= 19, n (SAL-URB)= 20, n (VPA-URB)= 19) and 90 (n (SAL-VEH)= 8, n (VPA-VEH)= 10, n (SAL-URB)= 8, n (VPA-URB)= 8).
Data represent mean± s.e.m. *Po0.05, **Po0.01, ***Po0.001 vs SAL-VEH group; §§Po0.01, §§§Po0.01 vs VPA-VEH group (Student’s t-test (a,
c, e and g); Student's–Newman–Keuls post hoc test (b, d, f and h)). PND, postnatal day; SAL, saline; VEH, vehicle; VPA, valproic acid.
Anandamide and autism spectrum disorders
M Servadio et al
7
Translational Psychiatry (2016), 1 – 11
characteristics; (2) in the three-chamber test that focuses on the
social approach of the experimental animal toward a confined
stimulus animal, without direct social contact.
In accordance with previous studies,15,32,41,57,58,61,66–69 the VPA-
exposed rats showed deficits in social behavior both at
adolescence and adulthood, as they showed decreased respon-
siveness to play solicitation and reduced sociability in the three-
chamber test. The reduced willingness to engage in social
interaction or to prolong a playful encounter displayed by VPA-
exposed rats are reminiscent of the altered social behavior and
deficient social play observed in autistic patients.1
The endocannabinoid system modulates different aspects of
social behavior. In humans, variations in the CB1 cannabinoid
receptor gene predict differences in the striatal response to happy
faces, indicating a role of the endocannabinoid system in social
reward responsivity.26,27 In addition, the endocannabinoid system
modulates amygdala reactivity to social threat signals.70 Altered
striatal and amygdala activity has been related to the diminished
response to social rewards displayed by autistic patients.71,72 In
line with this scenario, we found that VPA-exposed rats show
altered phosphorylation of CB1 cannabinoid receptors in the
dorsal striatum during all the lifespan, and in the amygdala both at
infancy and adulthood.
In rodents, anandamide has a positive modulatory role in
several social behavior: it is involved in pup USV production and
emotional reactivity,35,73 it is released during social play in the
amygdala, nucleus accumbens36 and dorsal striatum,74 and it is
involved in adult forms of social interactions.34,75 Interestingly, we
found that the expression of NAPE-PLD, the main anandamide
biosynthetic enzyme, was reduced in VPA-exposed rats from
infancy to adulthood; furthermore, VPA-exposed infant rats
showed higher expression of FAAH, the main enzyme involved
in anandamide catabolism. Thus, a reduced anandamide-
mediated signaling may underlie the deficits in the commu-
nicative and social domain displayed by VPA-exposed rats through
development. In line with this possibility, enhancing anandamide
activity through administration of the anandamide hydrolysis
inhibitor URB597 normalized the USV profile and the performance
of VPA-exposed pups in the homing test, and reversed their social
deficits in the three-chamber and social play behavior tests.
Stereotyped behaviors are the second core symptom displayed
by ASD patients.1 In accordance with previous studies,15,58,66,67,76
we found that both adolescent and adult rats prenatally exposed
to VPA showed stereotyped behavior in the hole-board test. It is
known that the endocannabinoid system is involved in motor
control by modulating dopaminergic neurotransmission in the
basal ganglia.77 In particular, increasing endocannabinoid signal-
ing by inhibiting endocannabinoid uptake or metabolism counter-
acts the stereotypies induced by systemic or intrastriatal
dopaminergic stimulation in rodents,78–80 whereas antagonism
at CB1 cannabinoid receptors increases dopamine receptor-
mediated stereotypies.81 In light of these findings, it is therefore
Figure 5. Elevated plus maze test. Prenatal VPA exposure decreased the percentage of time spent by the offspring in the open arms (a and e)
and the percentage of open-arm entries (b and f) in the elevated plus maze test at PND 35 (n (SAL)= 23, n (VPA)= 21) and 90 (n (SAL)= 13, n
(VPA)= 10). URB597 reversed the anxiety-like behavior displayed by VPA-exposed rats (c, d, g and h) at PND 35 (n (SAL-VEH)= 11, n (VPA-
VEH)= 11, n (SAL-URB)= 8, n (VPA-URB)= 8) and 90 (n (SAL-VEH)= 17, n (VPA-VEH)= 15, n (SAL-URB)= 13, n (VPA-URB)= 13). Data represent
mean± s.e.m. *Po0.05, **Po0.01, ***Po0.001 vs SAL-VEH group; §Po0.05, §§Po0.01 vs VPA-VEH group (Student’s t-test (a-f); Student's–
Newman–Keuls post hoc test (c–h)). PND, postnatal day; SAL, saline; VEH, vehicle; VPA, valproic acid.
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not surprising that the anandamide hydrolysis inhibitor URB597
counteracted the stereotyped behavior displayed by both
adolescent and adult VPA-exposed rats.
Anxiety is a frequent symptom displayed by autistic patients.2
Accordingly, as previously reported,41,66,82,83 the VPA-exposed rats
showed an anxious phenotype in the elevated plus maze test,
both during adolescence and adulthood.
Animal and clinical studies have repeatedly shown that the
endocannabinoid system is critically involved in the control of
emotionality.21 In particular, URB597 induces anxiolytic-like effects
in rodents,35,38,39 that become evident particularly when the
animals are tested under stressful conditions,84,85 supporting the
idea that endocannabinoids are released ‘on demand’, in response
to challenging situations. Interestingly, we found that URB597,
administered at a dose that had no effect in control animals,
reduced the anxious phenotype displayed by both adolescent and
adult VPA-exposed rats.
Collectively, three main conclusions can be drawn from the
present study. First, the altered behavioral profile displayed by
VPA-exposed rats from infancy till adolescence and adulthood is a
further preclinical proof of the long-lasting deleterious effects
induced by prenatal VPA exposure. To date, the potential for some
environmental factors to promote ASD is still relatively undeter-
mined, and the recent epidemiological data clearly show that the
public health protection strategies adopted so far have been
inadequate at best.17 Thus, targeted research on causative
environmental factors for ASD is warranted. Second, we report
abnormalities in brain anandamide activity in an environmental
animal model of ASD based on prenatal VPA exposure in rats.
These findings, that contribute to increase our understanding of
the neural underpinnings of ASD, extend previous studies
reporting altered endocannabinoid activity in animal models of
ASD28–32 and in ASD patients,33 and genetic studies in humans
showing an important role for cannabinoid receptors in proces-
sing appetitive socially relevant stimuli.26,27 Last, our results prove
that pharmacological interference with anandamide metabolism
mitigates in rats behavioral features that resemble the core and
associated symptoms of ASD. Thus, this study suggests that
abnormalities in anandamide activity may underlie the deleterious
impact of environmental risk factors on ASD-relevant behaviors,
and that the endocannabinoid system may be a therapeutic target
for the core and associated symptoms displayed by autistic
patients.
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